ADVANCE MIADdressing the Value of Facilitated ANgioplasty after Combination Therapy or Eptifibatide Monotherapy in Acute Myocardial Infarction. A clinical trial designed to evaluate the effect of combining emergent angioplasty < 6 hours post chest pain with half-dose thrombolytics in acute myocardial infarction; patients received a 50% standard dose of tenecteplase and eptifibatide—a gp IIb/IIIa inhibitor; in each treatment, patients received either open-label unfractionated heparin or open-label enoxaparin.
Conclusion The combined primary endpoint of death or severe congestive heart failure was 11% in eptifibatide + tenecteplase patients and 1% with eptifibatide-only patients (p = 0.02). Bleeding complications were significantly higher in eptifibatide + tenecteplase patients than in eptifibatide-only patients. The goal was to enroll 5,640 patients, but it was ended at 148 patients as the trial would not have been completed in a reasonable time frame.